{
    "clinical_study": {
        "@rank": "75593", 
        "arm_group": {
            "arm_group_label": "A", 
            "arm_group_type": "Experimental", 
            "description": "Volasertib (d1 and 15 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)"
        }, 
        "brief_summary": {
            "textblock": "To investigate the maximum tolerated dose (MTD), safety, pharmacokinetics, and efficacy of\n      volasertib in combination with azacitidine in patients with myelodysplastic syndromes (MDS)\n      or  chronic myelomonocytic leukemia (CMML) ineligible for high-intensity therapy"
        }, 
        "brief_title": "Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Myelodysplastic Syndromes", 
            "Leukemia, Myelomonocytic, Chronic"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myelomonocytic, Chronic", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        Adult patients with previously untreated, intermediate-2 or high- risk MDS or  CMML not\n        eligible for hematopoietic stem cell transplantation (HSCT) based on documented patients\n        characteristics like age, performance status, concomitant diagnoses, and organ\n        dysfunctions\n\n        Exclusion criteria:\n\n        Prior or concomitant therapy for higher risk MDS (for example, but not limited to,\n        hypomethylating agents like azacitidine).  Note: Prior treatment with Erythropoietin (EPO)\n        and iron- chelation is allowed up to >3 months before treatment with study medication.\n        Patients must have not received MDS therapy since diagnosis of higher-risk MDS. However,\n        previous lenalidomide treatment could have been administered for lower-risk MDS treatment\n        as long as this therapy was discontinued at least 12 months before initation of the\n        current study treatment.\n\n        Treatment with any investigational drug within 2 weeks before first administration of\n        present trial drug or within less than 5 half lives of the investigational drug before\n        treatment with the present trial drug, whichever is longer.\n\n        Second malignancy currently requiring active therapy (except for hormonal/anti-hormonal\n        treatment, e.g. in prostate or breast cancer).\n\n        Corrected QT interval according to Friederica (QTcF) prolongation > 470 ms or QT\n        prolongation deemed clinically relevant by the investigator (e.g., congenital long QT\n        syndrome).The QTcF will be calculated as the mean of the 3 Electrocardiograms (ECGs) taken\n        at screening.\n\n        Total bilirubin > 1.5 x upper limit of normal not related to Gilberts disease, hemolysis,\n        or secondary to MDS.\n\n        Aspartate amino transferase (AST) or alanine amino transferase (ALT) > 2.5 x the upper\n        limit of normal (ULN) Creatinine > 1.5 x ULN Active hepatitis B or hepatitis C, or\n        laboratory evidence for a chronic infection (hepatitis test results done in routine\n        diagnostics are acceptable if done within 14 days before first study treatment dose).\n\n        HIV infection (HIV test results in routine diagnostics are acceptable if done within 14\n        days before first study treatment dose).\n\n        Severe illness or organ dysfunction involving the kidney, liver or other organ system\n        (e.g. active uncontrolled infection , unstable angina pectoris or history of severe\n        congestive heart failure, clinically unstable cardiac disease or pulmonary disease),\n        which in the opinion of the investigator would interfere with the evaluation of the safety\n        of the study treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01957644", 
            "org_study_id": "1230.33", 
            "secondary_id": "2013-001290-24"
        }, 
        "intervention": [
            {
                "arm_group_label": "A", 
                "description": "Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)", 
                "intervention_name": "Azacitidine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "A", 
                "description": "Volasertib (d1 and 15 - one hour iv.)", 
                "intervention_name": "Volasertib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Azacitidine"
        }, 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France"
                    }, 
                    "name": "1230.33.33002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "1230.33.33001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany"
                    }, 
                    "name": "1230.33.49002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "D\u00fcsseldorf", 
                        "country": "Germany"
                    }, 
                    "name": "1230.33.49001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt/Main", 
                        "country": "Germany"
                    }, 
                    "name": "1230.33.49005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany"
                    }, 
                    "name": "1230.33.49004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ulm", 
                        "country": "Germany"
                    }, 
                    "name": "1230.33.49003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Germany"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Phase I Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics and Efficacy of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Patients With Previously Untreated High-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Ineligible for High-intensity Therapy", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Ethics Commission"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of dose limiting toxicity (DLT).", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Overall objective response (OR)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01957644"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}